Teva Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio
Teva Pharmaceuticals (Parsippany, NJ): 125 reconciled FDA prescription therapies (0.1% 2025 to 2030 cliff risk), $4.09B 2024 CMS Part D & Medicaid spend, and 137 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Parsippany, NJ |
| Reconciled FDA Portfolio Therapies | 125 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.1% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $4.09B |
| 2024 Medicare Part D Spend | $2.80B |
| 2024 Medicaid Spend | $1.29B |
| California HCAI SB 17 Filings | 137 WAC filings (max 125.8% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.